Written and edited by internationally recognized leaders in the field, the new edition of the Oxford Textbook of Oncology has been fully revised and updated, taking into consideration the advancements in each of the major therapeutic areas, and representing the multidisciplinary management of cancer.
Structured in six sections, the book provides an accessible scientific basis to the key topics of oncology, examining how cancer cells grow and function, as well as discussing the aetiology of cancer, and the general principles governing modern approaches to oncology treatment. The book examines the challenges presented by the treatment of cancer on a larger scale within population groups, and the importance of recognising and supporting the needs of individual patients, both during and after treatment.
A series of disease-oriented, case-based chapters, ranging from acute leukaemia to colon cancer, highlight the various approaches available for managing the cancer patient, including the translational application of cancer science in order to personalise treatment. The advice imparted in these cases has relevance worldwide, and reflects a modern approach to cancer care.
The Oxford Textbook of Oncology provides a comprehensive account of the multiple aspects of best practice in the discipline, making it an indispensable resource for oncologists of all grades and subspecialty interests.
 
About the Author
David J. Kerr, Professor of Cancer Medicine, Nuffield Division of Clinical and Laboratory Sciences, University of Oxford, UK,
Daniel G. Haller, Professor Emeritus, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA,
Cornelis J. H. van de Velde, Professor of Surgery and Head, Department of Surgical Oncology, Leiden University Medical Center, The Netherlands,
Michael Baumann, Professor and Chair, Department of Radiation Oncology; Director, University Cancer Center; and Coordinator, German Cancer Consortium (DKTK), Medical Faculty and University Hospital Carl Gustav Carus, Technical University of Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Germany; German Cancer Consortium (DKTK) partner site, Dresden, Germany; and German Cancer Center (DKFZ) Heidelberg, Germany,
Nagahiro Saijo, Professor, Kinki University School of Medicine; Member of Executive Advisory Board, West Japan Oncology Group; and Deputy Director of the National Can